🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Having had a Linkedin account for many many years, I finally godt around to do my first post today. Because I began as President of European Atherosclerosis Society January 1st 2025, I guess it was high time..... Some people get a slow start...sometimes I am one of them.

You can’t miss the first EAS Congress Latam. As members of the EAS Latam We will be honored to have you in this important event to be held in Cartagena de Indias in Colombia March 21 th. Prof Kausik Ray FMedSci Pablo Corral MD Borge G Nordestgaard clara saldarriaga European Atherosclerosis Society See you there!!

VLDL triglycerides predominate in NAFLD while VLDL cholesterol predominates in MI; however, VLDL cholesterol is also elevated slightly in NAFLD while VLDL triglycerides is also elevated in MI 🔗atherosclerosis-journal.com/article/S0021-… European Atherosclerosis Society Borge G Nordestgaard University of Copenhagen University of Copenhagen Research

Importance of remnant cholesterol on risk of ASCVD depends on size of remnants & larger TG-rich lipoproteins. Small remnants enter intima better than large TGRL. Metablolomics on N=25 572 from Copenhagen & N=222 721 from UK followed for 15-16 yrs. academic.oup.com/clinchem/advan…

High remnant cholesterol explains part of excess CHD in individuals with unhealthy lifestyle. Mia Ø Johansen & Copenhagen General Population Study in Lancet Reg Health Eur: authors.elsevier.com/sd/article/S26… 😀Live healthy! 😎Treat elevated remnant cholesterol if needed. 🧐Stay tuned.

Post hoc analyses of randomized trials may mislead: in PROMINENT/REDUCE-IT/STRENGTH combined, higher TG levels did not predict MACE; however, in the entire TG range in the Copenhagen General Population Study the corresponding relationship was clearcut: doi.org/10.1093/eurhea…

Being diagnosed with familial hypercholesterolemia (FH) by the DLCN criteria depends on smoking, hypertension, BMI, and triglyceride and lipoprotein(a) concentrations. Being a man (or woman) with FH and having several of these factors is not nice: authors.elsevier.com/c/1kbrX3Or0KfA…

An excellent reiew paper by Camilla Johannesen - on discordance analyses "Comparing LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B for Cardiovascular Risk Estimation" Published in Atherosclerosis. Wonderful simple explanations: authors.elsevier.com/c/1kl5w_Vu-kc34

Elevated remnant cholesterol (and not LDL cholesterol) had a causal effect on risk of PAD. Time to take elevated remnant cholesterol seriously? Look for high triglycerides to find the patients. authors.elsevier.com/a/1kpai2d9GI1v…

Great debate: Plasma triglycerides are an important causal factor and therapeutic target for atherosclerotic cardiovascular disease: Jan Boren+Chris Packard vs. Børge Nordestgaard. academic.oup.com/eurheartj/adva… Who wins? Here are the arguments - you decide - open acces

The cardiovascular risk from high lipoprotein(a) explained by LDL-C, non–HDL-C, apoB, or hsCRP is minimal. Therefore, it is essential that all individuals at cardiovascular risk have lipoprotien(a) measured: authors.elsevier.com/a/1k%7E7f_GjkR… Thomas PE in JACC open acces

The European Atherosclerosis Society Young Fellows have created a series of excellent podcasts - telling the more personal story of people whose research we sometimes read. Here is just one example, #11 and my own, one that I am very honored to have been invited to. Thanks!

EAS Congress late-breaking: In 273,770 US patients with ASCVD, higher Lp(a) levels drive continuously increasing risk of recurrent ASCVD events regardless of sex and race/ethnicity that may be partially mitigated by high impact LDL cholesterol lowering: academic.oup.com/eurheartj/adva…

JACC STATE-OF-THE-ART REVIEW: do you have problems understanding all the new drugs to lower triglycerides and remnant cholesterol: lipid and side effects, target populations, approved or not by FDA+EMA? Ask Tybjærg Nordestgaard et al explain the details authors.elsevier.com/a/1l4pB2d9GI27…

Huge potential for ASCVD reduction: in women and men a 2 mmol/L (77 mg/dL) lower remnant cholesterol likely reduce 10-year risk of ASCVD by 13–17% & 15–20%, more in statin users than in non-users academic.oup.com/eurjpc/advance… Karen Hvid et al use modelling in CGPS & publish in EJPC

A full house at #NLASessions for the W. Virgil Brown Distinguished Achievement Lectureship & Award.👏 Congratulations to this year’s recipient, Borge G Nordestgaard. We are honored to have you here in Miami!

In impaired renal function, low-grade inflammation and high remnant cholesterol jointly conferred highest risk of myocardial infarction, ASCVD, & all-cause mortality. D. Elías-López in Atherosclerosis atherosclerosis-journal.com/article/S0021-… CRP & remnant-C increase with lower kidney function:

Florian Kronenberg, Magda Daccord, et al made this important & influential document fly: "The Brussels International Declaration on Lipoprotein(a) Testing and Management". Patients, politicians, clinicians & sceintists: MEASURE Lp(A) IN ALL! atherosclerosis-journal.com/article/S0021-… Open access

Residual cardiovascular risk beyond low-density lipoprotein cholesterol: inflammation, remnant cholesterol, and lipoprotein(a). Mechanism driving ASCVD likely differ for LDL, remnants and Lp(a). academic.oup.com/eurheartj/adva… Anders B Wulff & BG Nordestgaard in Eur Heart J

Remnant cholesterol lowering is associated with part of the cardiovascular risk reduction in statin, ezetimibe, and PCSK9 inhibitor trials. A hitherto largely unnoticed clinically import fact: academic.oup.com/eurjpc/advance… AT Nordestgaard & BG Nordestgaard in Eur J Prevent Cardiol